Catalyst Wire Dossier Catalyst Wire Dossier

Evoximab

AK112
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Evoximab, covering 2024-04-30 to 2024-04-30. Get the full timeline:

Most recent: Clinical Trial Update: Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer [Phase 2]

See pricing